FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973642808> ?p ?o ?g. }

• W1973642808 endingPage "302" @default.
• W1973642808 startingPage "289" @default.
• W1973642808 abstract "The recent approval of rituximab, gemtuzumab ozogamicin, alemtuzumab and ibritumomab tiuxetan by the FDA in the US revealed clear evidence that monoclonal antibodies (mAbs) have significant roles in the current treatment of haematologic malignancies. Among the mAbs under clinical development, anti-CD20 mAbs have been most extensively investigated and have shown definitive clinical efficacy. Rituximab is a genetically engineered chimeric anti-CD20 mAb, with mouse variable and human constant regions. Consecutive clinical trials conducted in the US, Europe and Japan have revealed that rituximab is a highly effective agent with acceptable toxicities against indolent and aggressive B cell non-Hodgkin's lymphomas (B-NHLs) as a single agent and in combination with cytotoxic drugs. A recent French Phase III study in elderly patients with untreated aggressive B-NHL suggested that the addition of rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy increases the complete response rate and prolongs event-free and overall survival. Lymphoma cells are inherently sensitive to radiation. The aim of radioimmunotherapy is to use the mAb to target radiation to lymphoma tissue while minimising toxicity to normal cells. The clinical trials of 90Y ibritumomab tiuxetan and (131)I tositumomab showed they have definitive efficacy in relapsed indolent B-NHL with acceptable toxicities. A recent comparative study in relapsed indolent B-NHL showed that 90Y ibritumomab tiuxetan produces higher response rates than rituximab. In addition, BL22, a recombinant anti-CD22 immunotoxin, showed significant efficacy in patients with chemotherapy-resistant hairy cell leukaemia. MAbs will have significant roles in the treatment of lymphoid malignancies in the future." @default.
• W1973642808 created "2016-06-24" @default.
• W1973642808 creator A5036000764 @default.
• W1973642808 date "2002-10-01" @default.
• W1973642808 modified "2023-10-14" @default.
• W1973642808 title "Rituximab and other emerging monoclonal antibody therapies for lymphoma" @default.
• W1973642808 cites W1833241997 @default.
• W1973642808 cites W1842764967 @default.
• W1973642808 cites W1868627100 @default.
• W1973642808 cites W1892026381 @default.
• W1973642808 cites W1912693401 @default.
• W1973642808 cites W1915689252 @default.
• W1973642808 cites W1921508210 @default.
• W1973642808 cites W1942856476 @default.
• W1973642808 cites W1954038871 @default.
• W1973642808 cites W1963517571 @default.
• W1973642808 cites W1990066058 @default.
• W1973642808 cites W2002569913 @default.
• W1973642808 cites W2038465924 @default.
• W1973642808 cites W2050430487 @default.
• W1973642808 cites W2058015212 @default.
• W1973642808 cites W2060376769 @default.
• W1973642808 cites W2063157305 @default.
• W1973642808 cites W206701898 @default.
• W1973642808 cites W2067844151 @default.
• W1973642808 cites W2080585386 @default.
• W1973642808 cites W2084493022 @default.
• W1973642808 cites W2095113053 @default.
• W1973642808 cites W2099314298 @default.
• W1973642808 cites W2104746788 @default.
• W1973642808 cites W2104940816 @default.
• W1973642808 cites W2106542190 @default.
• W1973642808 cites W2107466475 @default.
• W1973642808 cites W2107990794 @default.
• W1973642808 cites W2110646221 @default.
• W1973642808 cites W2112628345 @default.
• W1973642808 cites W2116262245 @default.
• W1973642808 cites W2128402413 @default.
• W1973642808 cites W2128997140 @default.
• W1973642808 cites W2153596537 @default.
• W1973642808 cites W2161122282 @default.
• W1973642808 cites W2166984995 @default.
• W1973642808 cites W2168750246 @default.
• W1973642808 cites W2168926834 @default.
• W1973642808 cites W2169167811 @default.
• W1973642808 cites W2264636885 @default.
• W1973642808 cites W2267583049 @default.
• W1973642808 cites W2278214438 @default.
• W1973642808 cites W2320751441 @default.
• W1973642808 cites W2335889607 @default.
• W1973642808 cites W3082443879 @default.
• W1973642808 cites W329934425 @default.
• W1973642808 cites W4230324843 @default.
• W1973642808 cites W4241904210 @default.
• W1973642808 cites W4253332866 @default.
• W1973642808 cites W60759546 @default.
• W1973642808 doi "https://doi.org/10.1517/14728214.7.2.289" @default.
• W1973642808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15989552" @default.
• W1973642808 hasPublicationYear "2002" @default.
• W1973642808 type Work @default.
• W1973642808 sameAs 1973642808 @default.
• W1973642808 citedByCount "11" @default.
• W1973642808 countsByYear W19736428082017 @default.
• W1973642808 countsByYear W19736428082022 @default.
• W1973642808 crossrefType "journal-article" @default.
• W1973642808 hasAuthorship W1973642808A5036000764 @default.
• W1973642808 hasConcept C10205521 @default.
• W1973642808 hasConcept C126322002 @default.
• W1973642808 hasConcept C143998085 @default.
• W1973642808 hasConcept C159654299 @default.
• W1973642808 hasConcept C176290653 @default.
• W1973642808 hasConcept C18031839 @default.
• W1973642808 hasConcept C203014093 @default.
• W1973642808 hasConcept C2776146153 @default.
• W1973642808 hasConcept C2776694085 @default.
• W1973642808 hasConcept C2776755627 @default.
• W1973642808 hasConcept C2778515704 @default.
• W1973642808 hasConcept C2778623314 @default.
• W1973642808 hasConcept C2779015954 @default.
• W1973642808 hasConcept C2779338263 @default.
• W1973642808 hasConcept C2779429289 @default.
• W1973642808 hasConcept C2779725641 @default.
• W1973642808 hasConcept C2780653079 @default.
• W1973642808 hasConcept C28328180 @default.
• W1973642808 hasConcept C2911091166 @default.
• W1973642808 hasConcept C502942594 @default.
• W1973642808 hasConcept C542903549 @default.
• W1973642808 hasConcept C54355233 @default.
• W1973642808 hasConcept C71924100 @default.
• W1973642808 hasConcept C86803240 @default.
• W1973642808 hasConceptScore W1973642808C10205521 @default.
• W1973642808 hasConceptScore W1973642808C126322002 @default.
• W1973642808 hasConceptScore W1973642808C143998085 @default.
• W1973642808 hasConceptScore W1973642808C159654299 @default.
• W1973642808 hasConceptScore W1973642808C176290653 @default.
• W1973642808 hasConceptScore W1973642808C18031839 @default.
• W1973642808 hasConceptScore W1973642808C203014093 @default.
• W1973642808 hasConceptScore W1973642808C2776146153 @default.

• next